Impurezas de aminoácidos utilizados para sintetizar proteínas
Detalle do produto
| NO | Produtos | Nº CAS | Indicador clave de calidade | |||
| Pureza | Máx. impureza | Residuo total do disolvente | Humidade | |||
| 1 | Fmoc-β-Ala-Ala-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 2 | Fmoc-D-Ala-D-Ala-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 3 | Fmoc-β-Ala-D-Ala-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 4 | Fmoc-Arg(pbf)-Arg(pbf)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 5 | Fmoc-β-Ala-Arg(pbf)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 6 | Fmoc-D-Arg(pbf)-D-Arg(pbf)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 7 | Fmoc-β-Ala-D-Arg(pbf)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 8 | Fmoc-HomoArg(pbf)-HomoArg(pbf)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 9 | Fmoc-β-Ala-HomoArg(pbf)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 10 | Fmoc-Asn(Trt)-Asn(Trt)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 11 | Fmoc-β-Ala-Asn(Trt)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 12 | Fmoc-Asp(OtBu)-Asp(OtBu)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 13 | Fmoc-β-Ala-Asp(OtBu)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 14 | Fmoc-Cys(Trt)-Cys(Trt)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 15 | Fmoc-β-Ala-Cys(Trt)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 16 | Fmoc-Cys(Acm)-Cys(Acm)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 17 | Fmoc-β-Ala-Cys(Acm)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 18 | Fmoc-Gln(Trt)-Gln(Trt)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 19 | Fmoc-β-Ala-Gln(Trt)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 20 | Fmoc-Glu(OtBu)-Glu(OtBu)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 21 | Fmoc-β-Ala-Glu(OtBu)-OH.H2O | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 22 | Fmoc-β-Ala-Gly-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 23 | Fmoc-His(Trt)-His(Trt)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 24 | Fmoc-β-Ala-His(Trt)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 25 | Fmoc-Ile-Ile-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 26 | Fmoc-β-Ala-Ile-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 27 | Fmoc-Leu-Leu-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 28 | Fmoc-β-Ala-Leu-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 29 | Fmoc-D-Leu-D-Leu-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 30 | Fmoc-β-Ala-D-Leu-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 31 | Fmoc-Lys(Boc)-Lys(Boc)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 32 | Fmoc-β-Ala-Lys(Boc)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 33 | Fmoc-Lys(Aloc)-Lys(Aloc)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 34 | Fmoc-β-Ala-Lys(Alloc)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 35 | Fmoc-Met-Met-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 36 | Fmoc-β-Ala-Met-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 37 | Fmoc-Orn(Boc)-Orn(Boc)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 38 | Fmoc-β-Ala-Orn(Boc)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 39 | Fmoc-Phe-Phe-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 40 | Fmoc-β-Ala-Phe-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 41 | Fmoc-D-Phe-D-Phe-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 42 | Fmoc-β-Ala-D-Phe-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 43 | Fmoc-Pro-Pro-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 44 | Fmoc-β-Ala-Pro-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 45 | Fmoc-Ser(tBu)-Ser(tBu)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 46 | Fmoc-β-Ala-Ser(tBu)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 47 | Fmoc-Ser(Trt)-Ser(Trt)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 48 | Fmoc-β-Ala-Ser(Trt)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 49 | Fmoc-Thr(tBu)-Thr(tBu)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 50 | Fmoc-β-Ala-Thr(tBu)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 51 | Fmoc-Trp(Boc)-Trp(Boc)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 52 | Fmoc-β-Ala-Trp(Boc)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 53 | Fmoc-D-Trp(Boc)-D-Trp(Boc)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 54 | Fmoc-β-Ala-D-Trp(Boc)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 55 | Fmoc-Tyr(tBu)-Tyr(tBu)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 56 | Fmoc-β-Ala-Tyr(tBu)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 57 | Fmoc-D-Tyr(Et)-D-Tyr(Et)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 58 | Fmoc-β-Ala-D-Tyr(Et)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 59 | Fmoc-Tyr(Me)-Tyr(Me)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 60 | Fmoc-β-Ala-Tyr(Me)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 61 | Fmoc-Val-Val-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 62 | Fmoc-β-Ala-Val-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 63 | Fmoc-D-Cit-D-Cit-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 64 | Fmoc-β-Ala-D-Cit-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 65 | Fmoc-β-Ala-Dab-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 66 | Fmoc-(3-(2-naftil)-D-Ala)2-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 67 | Fmoc-β-Ala-3-(2-naftil)-D-Ala-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 68 | Fmoc-(3-(3-piridinil)-D-Ala)2-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 69 | Fmoc-β-Ala-3-(3-piridinil)-D-Ala-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 70 | Fmoc-(4-cloro-D-Phe)2-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 71 | Fmoc-β-Ala-4-cloro-D-Phe-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 72 | Fmoc-(D-4Aph(tBuCbm))2-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 73 | Fmoc-β-Ala-D-4Aph(tBuCbm)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 74 | Fmoc-Aph(L-Hor)-Aph(L-Hor)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 75 | Fmoc-β-Ala-Aph(L-Hor)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 76 | Fmoc-Lys(iPr,Boc)-Lys(iPr,Boc)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 77 | Fmoc-β-Ala-Lys(iPr,Boc)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 78 | Fmoc-β-Ala-AEEA-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 79 | Fmoc-Aib-Aib-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 80 | Fmoc-β-Ala-Aib-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 81 | Fmoc-Arg-OH | 91000-69-0 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 82 | H-Arg(pbf)-OH | 200115-86-2 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 83 | Fmoc-D-Arg-OH | 130752-32-8 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 84 | HD-Arg(pbf)-OH | 200116-81-0 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 85 | Fmoc-HomoArg-OH.HCl | 208174-14-5 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 86 | H-HomoArg(pbf)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 87 | Fmoc-D-HomoArg-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 88 | HD-HomoArg(pbf)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 89 | Fmoc-Asn-OH | 71989-16-7 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 90 | H-Asn(Trt)-OH | 132388-58-0 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 91 | Fmoc-Asp-OH | 119062-05-4 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 92 | H-Asp(OtBu)-OH | 3057-74-7 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 93 | Fmoc-Cys-OH | 135248-89-4 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 94 | H-Cys(Trt)-OH | 2799/7/7 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 95 | H-Cys(Acm)-OH.HCl | 28798-28-9 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 96 | Fmoc-Gln-OH | 71989-20-3 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 97 | H-Gln(Trt)-OH | 102747-84-2 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 98 | Fmoc-Glu-OH | 121343-82-6 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 99 | H-Glu(OtBu)-OH.H2O | 2419-56-9 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 100 | Fmoc-His-OH | 116611-64-4 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 101 | H-His(Trt)-OH | 35146-32-8 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 102 | Boc-His-OH | 17791-52-5 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 103 | Fmoc-Lys-OH | 105047-45-8 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 104 | H-Lys(Boc)-OH | 2418-95-3 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 105 | H-Lys(Aloc)-OH | 6298/3/9 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 106 | Fmoc-Orn-OH.HCl | 201046-57-3 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 107 | H-Orn(Boc)-OH | 13650-49-2 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 108 | Fmoc-Ser-OH | 73724-45-5 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 109 | H-Ser(tBu)-OH | 18822-58-7 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 110 | H-Ser(Trt)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 111 | Fmoc-Thr-OH.H2O | 73731-37-0 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 112 | H-Thr(tBu)-OH | 4378-13-6 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 113 | Fmoc-Trp-OH | 35737-15-6 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 114 | H-Trp(Boc)-OH | 146645-63-8 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 115 | Fmoc-D-Trp-OH | 86123-11-7 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 116 | HD-Trp(Boc)-OH | 201290-11-1 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 117 | Fmoc-Tyr-OH | 92954-90-0 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 118 | H-Tyr(tBu)-OH | 18822-59-8 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 119 | Fmoc-D-Tyr-OH | 112883-29-1 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 120 | HD-Tyr(Et)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 121 | H-Tyr(Me)-OH.HCl | 67423-44-3 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 122 | Fmoc-D-4Aph(Cbm)-OH | 324017-22-3 | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 123 | HD-4Aph (tBuCbm)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 124 | Fmoc-Lys(iPr)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
| 125 | H-Lys(iPr,Boc)-OH | NA | ≥98,0 % | ≤1,0 % | ≤8,0 % | ≤ 2,0 % |
Sobre
Compensación
Gentolex ofrece produtos de gran calidade, se o cliente suscita algunha calidade do produto no prazo esixido con evidencias suficientes, proporcionaremos a análise e avaliación necesarias para desencadear os procedementos de compensación.
Produción
As capacidades dos produtos farmacéuticos alcanzaron o grao de toneladas, as capacidades dos produtos químicos chegan a máis de 100 toneladas, as capacidades están ben equipadas para atender clientes en todo o mundo.
Investigación e desenvolvemento
Cada ano, hai un plan establecido polo equipo de I+D para desenvolver diferentes produtos novos, cando se establezan obxectivos, cada membro do equipo terá que continuar coa responsabilidade dos KPI e coa política de incentivos.
